Brief: Heidelberg Pharma And Huadong Medicine Receive Nmpa Approval For Hdp-101 Trial In China
26/08/2026 17:32
BRIEF-Heidelberg Pharma And Huadong Medicine Receive Nmpa Approval For Hdp-101 Trial In China Aug 26 (Reuters) - Heidelberg Pharma AG HPHA.DE:
HEIDELBERG PHARMA AG - AND HUADONG MEDICINE RECEIVE NMPA APPROVAL FOR HDP-101 TRIAL IN CHINA
Source text: ID:nEQ3CKZyha
Further company coverage: HPHA.DE
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Heidelberg Pharma AG
See all newsBrief: Heidelberg Pharma And Huadong Medicine Receive Nmpa Approval For Hdp-101 Trial In China
Germany's Heidelberg Pharma H1 sales revenue surges, driven by milestone payments
Brief: Heidelberg Pharma Says Co. And Healthcare Royalty Announce Amendment To Existing Royalty Agreement
Brief: Redhill Biopharma Secures Allowance Of Key Chinese Patent Application For Proprietary COVID-19 Treatment, RHB-107
Brief: Heidelberg Pharma Amends Royalty Financing With Healthcare Royalty